UBSIt appears UBS has slightly over 250,000 shares left to sell from their original purchase. They seem to want out and are no longer doing any research, it was a profitable trade for them. If you recall, they purchased a sizeable position around 85 cents. They will likely be all out of shares by weeks end or early next. Either way, the market is slow to add the full value of Ibalizumab - but they are clearly acknowledging the event. It is difficult to accumulate a sizeable amount of TH without moving the share price. If you look at the volume trends before EGRIFTA approval, you will see the stock doubled in price from $2-$4 on average daily volume of significantly less than today's average daily volume. I suspect once the UBS trade is through, the shares will get a nice bump as there are my long-term holders who will now stay the course for 5+ years in order to realize NPV from Ibalizumab. As for EGRIFTA, it is a cash cow that will produce net income at a fairly predictable rate for years to come. GLTA.